

Date: February 09, 2024

To
The Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

<u>Sub: Amendment in object clause and capital clause of the Memorandum of Association</u>
<u>- Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")</u>

Ref: Outcome of the Board Meeting dated 06th January 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended form time to time, we wish to inform you that the shareholders of the company in their Extraordinary General Meeting held on Wednesday, 31<sup>st</sup> January 2024, have approved the following amendments to Memorandum of Association ('MOA') of the Company.

- 1. Change in object clause of Memorandum of Association of the Company.
- 2. Increase in the Authorized share capital of the company and Alteration of Capital Clause of Memorandum of Association of the Company.

Further, the Brief details required under Regulation 30 of the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 on disclosure of material events/ information by listed entities, dated July 13, 2023 (SEBI Disclosure Circular) in respect of the aforesaid amendments to memorandum of association are enclosed herewith as **Annexure A** 

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)

## Annexure A

## **Brief summary of Amendments to Memorandum of Association of the Company**

Sr. No	Changes/Modification/Alteration
1.	The existing Main Objects under Clause III (A) under the head "The Main Objects of the Company to be pursued by the Company on its corporation" be altered by Substituting the same with the following new Clause III (A) as under:
	1. To engage in the production, manufacturing, trade of medicinal, pharmaceutical, chemical, agro goods, including but not limited to patent medicines, generic medicines, medical requisites, proprietary medicines, veterinary medicines, medical instruments, medical devices, photographic goods, oils, perfumes, cosmetics, extracts and other similar goods. Additionally, to conduct the business activities of packing, repacking, vialling, bottling and processing of tablets, capsules, syrups, injections, fluids, ointments, etc.
	2. To support, initiate, promote, and engage in product discovery, research, development, manufacturing, testing, analytical services like non-clinical, clinical, research services, innovation services, and other related activities in the domains of biotechnology, pharmaceuticals, devices, nutritional products, life sciences, chemical sciences, physical sciences, natural sciences, biosciences, agro-based products, and associated fields. This includes, but is not limited to, activities such as discovery, custom services, vivarium services, animal research, as well as preclinical and clinical studies and conducted invitro, on animals, human subjects.
	3. To conduct, facilitate, establish, pursue, develop, engage in, trade, utilize, consult, advise, and provide Contract Research and Manufacturing Services (CRAMS) including procurement, trading, breeding, production, of all requisite materials like active pharmaceutical ingredients, active ingredients, technical material, chemicals, laboratory animals, supplies etc.
	4. To build, establish, set up, lease, hire, or otherwise take possession of research, manufacturing, warehousing, and ancillary facilities. Additionally, to be involved in the business of designing and developing software and related products which may be specifically tailored for applications in the fields of pharma, healthcare, biotechnology, discovery, development, manufacturing, bioinformatics, automation, artificial intelligence and any related field.



## 2. **Increase in Authorised Share Capital**

The Existing Authorised Share Capital under Clause V is increased from Rs. 30,00,00,000/- (Rupees Thirty Crore Only) divided into 3,00,00,000 (Three Crore) Equity Shares of Rs. 10/- (Rupees Ten Only) to Rs. 45,00,00,000/- (Rupees Forty-Five Crore Only) divided into 4,50,00,000 (Four Crore Fifty Lakh) Equity Shares of Rs. 10/- (Rupees Ten Only) each and Consequential Alteration in the Capital Clause of the Memorandum of Association.

For Pharmaids Pharmaceuticals Limited

**Kaushik Kumar** (Company Secretary & Head-Legal)